A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children
de Whalley P, Walker W, Snape MD, Oeser C, Casey M, Moulsdale P, Harrill C, Andrews N, Hoschler K, Thompson B, Jones C, Chalk J, Kerridge S, Tomlinson R, Heath PT, Finn A, Faust S, Miller E, Pollard AJ
Record ID 32011000639
English
Authors' objectives:
This follow-on study will compare the A/California/7/2009 (H1N1) antibody persistence after these novel H1N1 influenza vaccines and immunogenicity&reactogenicity of one dose of a trivalent seasonal influenza vaccine, in cohorts receiving either Celvapen or Pandemrix to inform future H1N1 vaccination policy.
Authors' recommendations:
One year after immunisation, children receiving two doses of the routinely recommended, adjuvanted pandemic influenza vaccine had higher antibody levels than those receiving the alternative, egg-free vaccine; both groups produced a marked serological response to the H1N1 component of the 2010/11 seasonal influenza vaccine.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.hta.ac.uk/2369
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Child
- Infant
- Influenza A Virus, H1N1 Subtype
- Influenza Vaccines
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2011 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.